title: Fibrinolytic activity of oral cyclandelate in patients with generalized atherosclerotic vasculopathy: a double-blind study.
abstract: In a double-blind study, a single dose of 1600 mg cyclandelate or placebo was administered to 10 patients with cerebrovascular and/or peripheral vascular disease, and fibrinolytic activity was evaluated before and 1, 2, 4 and 6 h after treatment. Cyclandelate induced a reduction in euglobulin lysis time, an increase in tissue plasminogen activator concentration and a reduction in plasminogen activator inhibitor, alpha 2-antiplasmin and immunological fibrinogen concentrations, but no changes in antithrombin III and plasminogen concentrations were observed. After placebo administration no significant changes were observed. After treating two patients with 800 mg cyclandelate twice daily for 14 days, 1600 mg cyclandelate stimulated fibrinolysis for 8 h. It is concluded that the fibrinolytic activity of cyclandelate has implications for the treatment of cardiovascular complications of atherosclerosis.
authors.affiliation: Division of Gerontology and Geriatrics, University of Siena, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Forconi
authors.forename: R
authors.initials: R
authors.lastname: Cappelli
authors.forename: M
authors.initials: M
authors.lastname: Guerrini
authors.forename: C
authors.initials: C
authors.lastname: Frigerio
authors.forename: G L
authors.initials: GL
authors.lastname: Messa
authors.forename: L
authors.initials: L
authors.lastname: Furesi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000990:Antithrombin III / Q000378:metabolism; D001161:Arteriosclerosis / Q000150:complications*; D001774:Blood Chemical Analysis; D003495:Cyclandelate / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005340:Fibrinogen / Q000276:immunology / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012712:Serum Globulins / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014652:Vascular Diseases / Q000188:drug therapy* / Q000209:etiology; D000979:alpha-2-Antiplasmin / Q000378:metabolism
chemical_list: D005343:Fibrinolytic Agents; D012712:Serum Globulins; D000979:alpha-2-Antiplasmin; D003495:Cyclandelate; D000990:Antithrombin III; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator